-+ 0.00%
-+ 0.00%
-+ 0.00%

Microbot Medical Expands Commercial Team Ahead Of Anticipated Q3 2025 U.S. Launch of LIBERTY Robotic System; FDA 510(k) Decision Expected Q3 2025

Benzinga·06/09/2025 12:37:51
Listen to the news

Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance.